Tremblay AJ. Et al. J Lipid Res 2009 Mar 22 [Epub ahead of print]

Slides:

Advertisements

Similar presentations

Secretory Phospholipase A2: A New Risk Factor and Soon a New Target of Therapy Rabih R. Azar, MD, MSc, FACC Associate Professor of Medicine Division of.

Advertisements

Flow chart showing number of citations retrieved by individual searches and number of trials included in review Strippoli GF, et al. BMJ 2008 Feb 25 [Epub.

Difference in lipid metabolism and atherosclerosis among human, rodents, and WHHL / WHHLMI rabbits.

The concept of Diabetes & CV risk: A lifetime risk challenge Vascular function as an early sign of trouble: How can the inhibition of cholesterol absorption.

New (U.S.) Lipid Guidelines (The Good and Bad) Robert A. Vogel, MD Clinical Professor of Medicine University of Colorado Denver Disclosures: National Coordinator.

Lipid Disorders and Management in Diabetes

Pathway of Exogenous Cholesterol Metabolism

Lipoproteins/Particles

Downloaded from Slide 1 Dual Inhibition of Two Sources of Cholesterol: Absorption and Production in Patients with Type 2 Diabetes.

Slide 1 EZT 2002-W-6022-SS Ezetimibe Co-administered with Statins: Efficacy and Tolerability Copyright © 2003 MSP Singapore Company, LLC. All rights reserved.

SECONDARY PREVENTIONS Jaimon Stucki MS-1 PSCOM. Blood Draw.

Slide 1 Downloaded from Ezetimibe Factorial Coadministration Studies.

Copyright® Raisio A plant stanol yogurt drink alone or combined with a low-dose statin lowers serum triacylglycerol and non-HDL cholesterol.

C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June.

Baseline Characteristics of Cases, Controls, and Entire VA-HIT Population James D. Otvos, et al, Circulation 2006;113:

Copyright® Raisio Effects of long-term plant sterol or stanol ester consumption on lipid and lipoprotein metabolism in subjects on statin treatment.

Yunoki K et al. Atherosclerosis 2011 Epub Apr 22.

Copyright® Raisio Reduction of serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced.

Parish S, et al. Eur Heart J 2009 [Epub ahead of print]

Ezetimibe Overall Conclusions

Downloaded from Slide 1 Dual Inhibition of Two Sources of Cholesterol: Absorption and Production Results of a Clinical Trial.

Trial profile SAS denotes the Simvastatin in Aortic Stenosis Study

Westerweel PE et al. Eur Heart J 2008;29:

Switch from EFV plus ABC-3TC to EFV-TDF-FTC ROCKET-1 Trial

Switching to TDF-FTC from ABC-3TC for Hyperlipidemia ROCKET II

The Latest Lipid Guidelines:

Anti-Hypercholesterolemic Agents

Scandinavian Simvastatin Survival Study (4S)

The ASSERT Study.

Volume 93, Issue 6, Pages (June 2018)

Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY.

Effect of evolocumab on lipoprotein particles

Placebo group 5-mg rimonabant group p 20-mg rimonabant group

Figure 2. Plasma lipoprotein cholesterol in apo-E −/− mice with CRF

Evaluating LDL-C Recommendations

Section 7: Aggressive vs moderate approach to lipid lowering

ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,

Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia Joep C. Defesche, PhD,

Jun M, et al. Lancet 2010 Epub May 10

Marina Cuchel, Dirk J. Blom, Maurizio R. Averna

A) Exhaled nitric oxide fraction (FeNO) before and after 9 weeks of treatment; b) percentage change in forced expiratory volume in 1 s (FEV1) following.

TACTICS-HF Trial design: Patients with acute heart failure (reduced or preserved ejection fraction) were randomized to tolvaptan 30 mg at 0, 24, and 48.

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

Préparation ESC Septembre

OSLER Trial design: Patients from five phase 2 trials and seven phase 3 trials with evolocumab were invited to participate in the OSLER extension program,

Hajer GR et al. Atherosclerosis 2009;202:216-24

Sudhop T. et al. J Lipid Res 2009 Apr 20 [Epub ahead of print]

Classification of statins/dosages according to the attainable

Figure 1 Statins, ezetimibe, and PCSK9 inhibitors all increase the expression of LDL receptors and reduce LDL-cholesterol levels (by percentages shown)

Potential mechanisms whereby statins may reduce the risk of stroke

Recommendations for the management of patients with homozygous familial hypercholesterolaemia: Overview of a new European Atherosclerosis Society consensus.

Body mass, BMI, plasma lipids, lipoproteins, and glucose homeostasis at baseline, and following placebo and rosuvastatin periods Dmitri Sviridov et al.

ACR response rates at 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination with cDMARDs or MTX. The proportions of patients.

RUTHERFORD-2 Trial design: Patients with heterogeneous familial hypercholesterolemia (HeFH) on statins were randomized in a 2:2:1:1 fashion to subcutaneous.

Baseline Clinical Characteristics

Disposition of Patients in the Atherogenic Dyslipidemia Study

(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.

Characteristics of Large Randomized Controlled Statin Trials Included in the Present Analysis Alawi A. et al. JACC 2008 Aug 20 [Epub ahead of print]

Telaprevir in Treatment Experienced GT-1 PROVE3

Simvastatin With or Without Ezetimibe in Familial Hypercholesterolemia

Updates on Dyslipidemia

Titration activities from baseline up to 6 and 12 months follow-up in nurse-coordinated care (NCC) versus usual care patients. X-as: patients (percentage),

Change in APOC3 level in response to treatment with APOC3 antisense oligonucleotide ISIS Phase 2, randomised, double-blind, placebo-controlled study.

Change in markers of glycometabolism and cardiovascular risk profile.

Correlation between progranulin (dependent variable) and CKD stage adjusted for age and sex, as well as DBP, WHR, triglycerides, HDL cholesterol, LDL cholesterol,

Flow of study participants

PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies.

© The Author(s) Published by Science and Education Publishing.

Correlations of the breast cancer hypoxia metagene with Ki67 and the proliferation metagene. Correlations of the breast cancer hypoxia metagene with Ki67.

Spasticity as measured by mean combined scores on the modified Ashworth scale, before and after treatment, on each day of each phase of the trial. Spasticity.

Presentation transcript:

Tremblay AJ. Et al. J Lipid Res 2009 Mar 22 [Epub ahead of print]

Lipid/Lipoprotein Profile After a 6-Week Treatment with Ezetimibe (10 mg/d) and Simvastatin (40 mg/d), Simvastatin (40 mg/d) alone, Ezetimibe (10 mg/d) alone and Placebo Tremblay AJ. Et al. J Lipid Res 2009 Mar 22 [Epub ahead of print]

Kinetic parameters of ApoB-100 in VLDL, IDL, and LDL and ApoB-48 in TRL following the Placebo, Ezetimibe (10 mg) alone, Simvastatin (40 mg) alone and Ezetimibe (10 mg) plus Simvastatin (40 mg) treatment phases Tremblay AJ. Et al. J Lipid Res 2009 Mar 22 [Epub ahead of print]

Effect of 10 mg/d of ezetimibe, 40 mg/d of simvastatin and 10 mg/d of ezetimibe plus 40 mg/d of simvastatin on markers of cholesterol synthesis and intestinal absorption Tremblay AJ. Et al. J Lipid Res 2009 Mar 22 [Epub ahead of print]

Correlation between percentage changes in TRL apoB-48 pool size and percentage changes in TRL apoB-48 production rate following combination therapy with ezetimibe (10 mg/day) and simvastatin (40 mg/day) versus placebo Tremblay AJ. Et al. J Lipid Res 2009 Mar 22 [Epub ahead of print]

Correlation between percentage changes in LDL apoB-100 pool size and percentage changes in LDL apoB-100 fractional catabolic rate following combination therapy with ezetimibe (10 mg/day) and simvastatin (40 mg/day) versus placebo Tremblay AJ. Et al. J Lipid Res 2009 Mar 22 [Epub ahead of print]